Oncolytic Viruses for Multiple Myeloma Therapy
AbstractAlthough recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM therapy with a focus on those agents that have advanced into clinical trials. View Full-Text
Share & Cite This Article
Calton, C.M.; Kelly, K.R.; Anwer, F.; Carew, J.S.; Nawrocki, S.T. Oncolytic Viruses for Multiple Myeloma Therapy. Cancers 2018, 10, 198.
Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST. Oncolytic Viruses for Multiple Myeloma Therapy. Cancers. 2018; 10(6):198.Chicago/Turabian Style
Calton, Christine M.; Kelly, Kevin R.; Anwer, Faiz; Carew, Jennifer S.; Nawrocki, Steffan T. 2018. "Oncolytic Viruses for Multiple Myeloma Therapy." Cancers 10, no. 6: 198.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.